Online citations, reference lists, and bibliographies.

Diagnostic Utility Of Cerebrospinal Fluid &agr;‐synuclein In Parkinson's Disease: A Systematic Review And Meta‐analysis

P. Eusebi, David Giannandrea, Leonardo Biscetti, I. Abraha, D. Chiasserini, M. Orso, P. Calabresi, L. Parnetti
Published 2017 · Medicine, Psychology

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The accumulation of misfolded α-synuclein aggregates is associated with PD. However, the diagnostic value of the α-synuclein levels in CSF is still under investigation. METHODS A comprehensive search of the literature was performed, yielding 34 studies eligible for meta-analysis. We included studies that reported data on CSF total, oligomeric and phosphorylated α-synuclein in patients with PD and healthy participants, neurological controls, or other parkinsonisms. Standardized mean differences were pooled using random-effects models, and heterogeneity was reported as I2 . Bivariate random effects meta-analysis was also performed on diagnostic data. Methodological quality of the selected studies was assessed using the QUADAS-2 tool. RESULTS Concentrations of α-synuclein species in PD did not show significant differences with respect to the levels found in other parkinsonisms. Total α-synuclein was significantly reduced in PD when compared with controls (standardized mean differences -0.48; P < .001, I2 = 60%). Oligomeric (standardized mean differences 0.57; P < .001, I2 = 44%) and phosphorylated α-synuclein (standardized mean differences 0.86; P < .001) were significantly increased in PD when compared with controls. Sensitivity and specificity for distinguishing PD and controls were 0.72 and 0.65, respectively, for total α-synuclein, and 0.71 and 0.64, respectively, for oligomeric α-syn. CONCLUSION Most of the studies were at high risk of bias and have concerns regarding applicability. Diagnostic performance of CSF α-synuclein species is still below what would be considered acceptable for their introduction in clinical practice. Future research should focus on combining α-synuclein species with other biochemical markers as well on improving the standardization of current assays. © 2017 International Parkinson and Movement Disorder Society.
This paper references
10.1016/J.YNEU.2012.04.042
Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
B. Robottom (2012)
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.
M. Spillantini (1998)
10.1186/1471-2288-14-135
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
X. Wan (2014)
10.1002/mds.25772
Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
L. Parnetti (2014)
10.1136/bmj.b2535
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
D. Moher (2009)
10.1038/srep26145
Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of baseline data
Steffen Halbgebauer (2016)
10.1371/journal.pone.0138237
The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching
Neal R Haddaway (2015)
Phosphorylated alpha-Synuclein in Parkinson's Disease
Yu Wang (2012)
10.1007/s00415-014-7560-z
Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease
Y. Compta (2014)
10.1136/jnnp-2014-309562
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
N. Magdalinou (2015)
10.1016/j.neulet.2012.11.004
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
B. Mollenhauer (2013)
10.1001/ARCHNEUROL.2012.1654
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
S. Hall (2012)
10.1016/S1474-4422(11)70014-X
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
B. Mollenhauer (2011)
10.1212/WNL.0000000000001308
Parkinson disease with REM sleep behavior disorder
Y. Hu (2015)
10.3389/fnagi.2014.00248
Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
J. Aasly (2014)
10.1001/ARCHNEUR.56.1.33
Diagnostic criteria for Parkinson disease.
D. Gelb (1999)
10.1016/j.neurobiolaging.2014.07.043
Correlation between decreased CSF α-synuclein and Aβ1–42 in Parkinson disease
Chandana Buddhala (2015)
10.1016/J.JCLINEPI.2005.02.022
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.
J. Reitsma (2005)
10.1136/BMJ.38636.593461.68
Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources
T. Greenhalgh (2005)
10.1212/WNL.0000000000002876
Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
K. Jellinger (2016)
10.1111/ane.12590
Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review
A. D. Andersen (2017)
10.1016/S0140-6736(09)60492-X
Parkinson's disease
A. Lees (2006)
10.3109/00207454.2014.961454
Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis
L. Gao (2015)
10.1371/journal.pone.0053250
Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy
Malin Wennström (2013)
10.1001/jamaneurol.2015.1449
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
D. Bäckström (2015)
10.1002/mds.26591
Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
D. Vilas (2016)
10.1016/j.parkreldis.2015.04.027
Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Ane Løvli Stav (2015)
10.7326/0003-4819-155-8-201110180-00009
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
P. Whiting (2011)
10.1136/jnnp.55.3.181
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A. Hughes (1992)
10.1177/0891988716632918
Excessive Iron and α-Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease
F. Wang (2016)
10.1212/WNL.0b013e3181fd613b
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda (2010)
10.1007/s00415-016-8259-0
Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies
F. Llorens (2016)
10.1038/nrneurol.2013.10
Cerebrospinal fluid biomarkers in Parkinson disease
L. Parnetti (2013)
10.1186/s13024-016-0072-9
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
N. Majbour (2016)
10.2174/138920308785915218
α-Synuclein Misfolding and Neurodegenerative Diseases
V. Uversky (2008)
10.1093/BRAIN/AWF080
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.
A. Hughes (2002)
10.1097/WAD.0b013e31823899cc
Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease
F. Tateno (2012)
10.1155/2015/567386
The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α-Synuclein Levels in Parkinson's Disease: A Meta-Analysis
B. Zhou (2015)
10.1016/j.parkreldis.2014.01.011
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
S. Mondello (2014)
10.1007/s00401-016-1552-2
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
Ju-Hee Kang (2016)
10.1074/mcp.M116.059915
Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies*
Patrick Oeckl (2016)
10.3233/JAD-2010-100186
CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
F. Reesink (2010)
10.1016/j.neurobiolaging.2010.12.001
CSF α-synuclein does not differentiate between parkinsonian disorders
M. Aerts (2012)
10.1002/mds.23670
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
L. Parnetti (2011)
10.2217/bmm.15.107
Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
L. Parnetti (2016)
10.3988/jcn.2011.7.4.215
Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease
M. J. Park (2011)
10.1590/0004-282X20150029
Non-motor signs in Parkinson's disease: a review.
R. Munhoz (2015)
10.1111/j.1471-4159.2012.07749.x
Cerebrospinal fluid α‐synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase
Honghao Wang (2012)
10.1002/mds.26578
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
S. Hall (2016)
CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease
FE Reesink (2010)
Alpha-synuclein misfolding and neurodegenerative diseases.
V. Uversky (2008)
10.1136/bmjopen-2016-011113
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
P. Eusebi (2016)
10.1016/j.neulet.2008.11.015
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
A. Öhrfelt (2009)
10.1126/scitranslmed.3002566
Phosphorylated α-Synuclein in Parkinson’s Disease
Yu Wang (2012)
10.1002/mds.26036
Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
W. Sako (2014)
10.1111/ene.12176
Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity
K. D. Dijk (2014)
10.2217/FNL.14.51
Cerebrospinal fluid α-synuclein in the differential diagnosis of parkinsonian syndromes
N. Heegaard (2014)
10.1073/PNAS.95.11.6469
α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies
M. Spillantini (1998)
10.1016/j.expneurol.2008.06.004
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
B. Mollenhauer (2008)
10.1002/mds.25945
The prevalence of Parkinson's disease: a systematic review and meta-analysis.
T. Pringsheim (2014)
10.1016/j.parkreldis.2014.04.019
Diagnostic accuracy of parkinsonism syndromes by general neurologists.
J. Joutsa (2014)



This paper is referenced by
10.1038/s41582-020-0348-0
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
N. Ashton (2020)
10.1016/j.cca.2019.04.078
Parkinson's and Lewy body dementia CSF biomarkers.
L. Parnetti (2019)
10.3390/cells8111317
Autophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows
Helena Xicoy (2019)
10.1101/743856
Severe Hyposmia Distinguishes Neuropathologically Confirmed Dementia with Lewy Bodies from Alzheimer’s Disease Dementia
T.G. Beach (2019)
10.1002/psp4.12538
Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain
M. Kuchimanchi (2020)
The biology of cognitive decline and reduced survival in Parkinson disease : prognostic factors in a population-based cohort
David Bäckström (2019)
10.1080/14737175.2017.1392239
Potential clinical utility of multiple system atrophy biomarkers
K. Jellinger (2017)
10.3390/ijms20133148
Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases
T. Hosaka (2019)
10.1186/s12916-018-1016-8
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
K. Jellinger (2018)
10.1126/scitranslmed.aay3069
APOE genotype regulates pathology and disease progression in synucleinopathy
A. Davis (2020)
10.1111/jnc.14569
Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study
B. Mollenhauer (2019)
10.1111/jnc.14965
Synucleinopathies: Where we are and where we need to go.
I. C. Brás (2020)
10.1101/510453
Faster Cognitive Decline in Dementia due to Alzheimer Disease with Clinically Undiagnosed Lewy Body Disease
T. Beach (2019)
10.1016/j.neurobiolaging.2018.09.018
Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling
Mercedes Lachén-Montes (2019)
10.1016/j.neulet.2019.134564
Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson’s disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings
T. Katayama (2020)
10.1111/ene.14032
The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology
M. Førland (2019)
10.1038/s41598-019-42399-0
Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
Keita Kakuda (2019)
10.1186/s13195-020-00586-6
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg
Pawel Obrocki (2020)
10.1080/14737159.2020.1721283
If not salivary alpha-synuclein, then what? A look at potential Parkinson’s disease biomarkers
A. Bougea (2020)
10.1002/mds.27485
Importance of low diagnostic Accuracy for early Parkinson's disease.
T. Beach (2018)
10.1016/j.cca.2020.03.002
Molecular profiling in Parkinsonian syndromes: CSF biomarkers.
Federico Paolini Paoletti (2020)
10.2217/FNL-2018-0003
Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies
F. N. Sepe (2018)
10.1101/2020.07.01.20144493
Genome-wide association, Mendelian Randomization and polygenic risk score studies converge on a role of beta-amyloid and APOE locus in Parkinson disease
L. Ibanez (2020)
10.1101/846014
A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol
Christoph Gerdes (2019)
10.3389/fneur.2018.00295
Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
V. Ghiglieri (2018)
10.1007/s00415-018-8847-2
Alpha-synuclein is present in dental calculus but not altered in Parkinson’s disease patients in comparison to controls
Sabrina Schmid (2018)
10.1038/s41598-018-35376-6
Cerebrospinal Fluid Levels of Autophagy-related Proteins Represent Potentially Novel Biomarkers of Early-Stage Parkinson’s Disease
J. Youn (2018)
10.3390/biom10020335
The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
Federico Paolini Paoletti (2020)
10.1002/prp2.470
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
Fernando L. Pagan (2019)
10.1016/S1474-4422(19)30024-9
CSF and blood biomarkers for Parkinson's disease
L. Parnetti (2019)
10.1016/j.bbr.2019.02.039
Diagnostic utility of gut α-synuclein in Parkinson’s disease: A systematic review and meta-analysis
Jin Bu (2019)
10.1038/s41582-018-0058-z
Neurofilaments as biomarkers in neurological disorders
M. Khalil (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar